Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37928429)

  • 1. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
    Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
    J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
    [No Abstract]   [Full Text] [Related]  

  • 2. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
    Wu JJ; Wang WH; Dong M; Ma SS; Zhang XD; Zhu LN; Niu ST; Ding MJ; Zhang JM; Zhang L; Li X; Li L; Sun ZC; Wang XH; Fu XR; Li ZM; Chang Y; Nan FF; Yan JQ; Yu H; Wu XL; Zhou ZY; Zhang MZ
    Invest New Drugs; 2022 Jun; 40(3):650-659. PubMed ID: 35137332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the Short-Term Efficacy and Safety of Orelabrutinib Combined with High-Dose Methotrexate in the First-line Treatment of Elderly Patients with High Risk Primary Central Nervous System Lymphoma].
    Xie Y; Qu S; Liao LS; Zheng ZH; Lin Y; Chen WM; Chen BY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1714-1719. PubMed ID: 38071050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.
    Yang C; Cui Y; Ren X; Li M; Yu K; Shen S; Jiang H; Li M; Zhang X; Zhao X; Zhu Q; Lin S
    Front Oncol; 2022; 12():901797. PubMed ID: 35785180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis.
    Wei R; Wu Y; Jiang S; Zhang A; Zhang L; Liu L; Wang Y; Zhang M; Mei H; Liu F; Xia L; Cui G; Fang J
    Clin Exp Med; 2023 Dec; 23(8):4609-4621. PubMed ID: 37925380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
    Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and survival analysis of DICE regimen for 97 patients with relapsed or refractory Non-Hodgkin's lymphoma].
    Ping LY; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ying ZT; Liu WP; Zhang C; Deng LJ; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):790-794. PubMed ID: 27719723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
    Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
    Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.
    Hou K; Yu Z; Jia Y; Fang H; Shao S; Huang L; Feng Y
    Crit Rev Oncol Hematol; 2020 Aug; 152():103010. PubMed ID: 32540781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis.
    Qiao L; Liu Q; Huang C
    Medicine (Baltimore); 2023 Jul; 102(27):e33880. PubMed ID: 37417642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
    Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
    Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.
    Dietrich J; Versmee L; Drappatz J; Eichler AF; Nayak L; Norden A; Wong E; Pisapia MR; Jones SS; Gordon AB; Chabner BA; Hochberg F; Batchelor TT
    Oncologist; 2020 Sep; 25(9):747-e1273. PubMed ID: 32520407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.
    Lv L; Sun X; Wu Y; Cui Q; Chen Y; Liu Y
    Front Oncol; 2021; 11():707285. PubMed ID: 34277452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of
    Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y
    Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
    Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
    Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.